We are live on ! Find out more
ARKG icon

ARK Genomic Revolution ETF

460 hedge funds and large institutions have $1.39B invested in ARK Genomic Revolution ETF in 2021 Q4 according to their latest regulatory filings, with 98 funds opening new positions, 101 increasing their positions, 200 reducing their positions, and 97 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.77% more ownership

Funds ownership: 24.28%27.06% (+2.8%)

1% more first-time investments, than exits

New positions opened: 98 | Existing positions closed: 97

2% less funds holding

Funds holding: 468460 (-8)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

20% less capital invested

Capital invested by funds: $1.74B → $1.39B (-$353M)

50% less repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 200

69% less call options, than puts

Call options by funds: $144M | Put options by funds: $460M

Holders
460
Holders Change
-8
Holders Change %
-1.71%
% of All Funds
7.08%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
98
Increased
101
Reduced
200
Closed
97
Calls
$144M
Puts
$460M
Net Calls
-$316M
Net Calls Change
-$158M
Name Holding Trade Value Shares
Change
Change in
Stake
SWM
151
Spire Wealth Management
Virginia
$804K -$79.7K -1,153 -8%
Rockefeller Capital Management
152
Rockefeller Capital Management
New York
$777K -$145K -2,104 -14%
ACM
153
Anfield Capital Management
California
$768K +$10.2K +147 +1%
AA
154
Ancora Advisors
Ohio
$760K -$656K -9,482 -43%
BWM
155
Bulltick Wealth Management
Florida
$751K +$588K +8,500 +226%
SB
156
Strategic Blueprint
Georgia
$749K +$310K +4,486 +58%
TFA
157
Teamwork Financial Advisors
Texas
$746K -$275K -3,973 -25%
CIC
158
Carnegie Investment Counsel
Ohio
$741K -$804K -11,624 -49%
NEPWA
159
New England Private Wealth Advisors
Massachusetts
$720K +$760 +11 +0.1%
HF
160
HRT Financial
New York
$716K -$11.5M -165,873 -93%
PWM
161
Perigon Wealth Management
California
$702K -$69.2K -1,001 -8%
NWA
162
Navis Wealth Advisors
New York
$696K -$266K -3,853 -25%
WWM
163
Western Wealth Management
Colorado
$692K +$782K +11,309 New
CWC
164
Carolinas Wealth Consulting
North Carolina
$689K -$27K -390 -3%
LWM
165
Laidlaw Wealth Management
New York
$661K +$24.7K +358 +3%
CA
166
Clearstead Advisors
Ohio
$653K -$356K -5,153 -33%
WI
167
Wintrust Investments
Illinois
$653K +$737K +10,660 New
CMS
168
Capital Market Strategies
Florida
$652K +$736K +10,645 New
AAS
169
Avantax Advisory Services
Texas
$650K -$293K -4,238 -29%
SEA
170
Stegent Equity Advisors
Texas
$648K +$731K +10,575 New
Millennium Management
171
Millennium Management
New York
$642K -$3.67M -53,036 -83%
FFWA
172
FRG Family Wealth Advisors
Washington
$639K -$170K -2,452 -19%
SDH
173
Sloy Dahl & Holst
Washington
$635K
CWM
174
Calamos Wealth Management
Illinois
$632K -$176K -2,553 -20%
CAM
175
Cresset Asset Management
Illinois
$631K +$253K +3,658 +55%

ARKG Hedge Fund Activity: Q4 2021 in Review

460 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2021, worth a combined $1.39B — down 20% from $1.74B a quarter earlier.

Buyers outnumbered sellers: 98 funds opened new ARKG positions and 97 closed out — a net gain of 1 holder — while 101 added to existing stakes and 200 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $37.5M. The largest seller was Bank of America, cutting an estimated $29.1M.

  • 460 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2021, down from 468 in Q3 2021.
  • Funds reported $1.39B of ARK Genomic Revolution ETF stock for Q4 2021, down 20% quarter-over-quarter.
  • 98 funds opened new ARK Genomic Revolution ETF positions in Q4 2021 and 97 closed out, a net change of +1 holder.
  • The largest ARK Genomic Revolution ETF buyer in Q4 2021 was BNP Paribas Financial Markets, an estimated $37.5M added.
  • The largest ARK Genomic Revolution ETF seller in Q4 2021 was Bank of America, an estimated $29.1M sold.

Based on aggregated 13F filings for Q4 2021.